{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:45:46Z","timestamp":1785915946861,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014901","name":"Hubei University of Arts and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.slasd.2026.100322","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:47:25Z","timestamp":1781801245000},"page":"100322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumor-versus-nonmalignant quantitative drug sensitivity profiling identifies capivasertib as a selective therapeutic candidate for nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"42","author":[{"given":"Haiying","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.slasd.2026.100322_bib0001","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10555-024-10176-9","article-title":"Epidemiology of nasopharyngeal carcinoma: current insights and future outlook","volume":"43","author":"Su","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.slasd.2026.100322_bib0002","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1186\/s12967-025-06549-5","article-title":"EBV reactivation-associated gene signature predicts poor prognosis in nasopharyngeal carcinoma","volume":"23","author":"Luo","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.slasd.2026.100322_bib0003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaoncol.2023.6552","article-title":"Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial","volume":"10","author":"Dai","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.slasd.2026.100322_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202500460","article-title":"Targeting ferroptosis in nasopharyngeal carcinoma: mechanisms of therapy resistance and therapeutic opportunities","volume":"9","author":"Zheng","year":"2025","journal-title":"Adv Biol"},{"key":"10.1016\/j.slasd.2026.100322_bib0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/curroncol32090479","article-title":"Novel therapeutic development for nasopharyngeal carcinoma","volume":"32","author":"Kim","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.slasd.2026.100322_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12032-025-02610-x","article-title":"Epstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications","volume":"42","author":"Mark","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.slasd.2026.100322_bib0007","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"key":"10.1016\/j.slasd.2026.100322_bib0008","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"Tyner","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.slasd.2026.100322_bib0009","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.slasd.2026.100322_bib0010","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2026.100322_bib0011","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.slasd.2026.100322_bib0012","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-14-3763","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method\u2013letter","volume":"75","author":"Ashton","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.slasd.2026.100322_bib0013","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12916-025-04103-0","article-title":"Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial","volume":"23","author":"Zou","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.slasd.2026.100322_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.16094","article-title":"Long-term outcomes of Bevacizumab and chemoradiation for locoregionally advanced nasopharyngeal carcinoma: a nonrandomized controlled trial","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.slasd.2026.100322_bib0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/1440-1681.13649","article-title":"Inhibition of mTOR by temsirolimus overcomes radio-resistance in nasopharyngeal carcinoma","volume":"49","author":"Huang","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.slasd.2026.100322_bib0016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/ph16010037","article-title":"Afatinib reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma","volume":"16","author":"Huang","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.slasd.2026.100322_bib0017","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-019-0827-1","article-title":"Simultaneously inactivating Src and AKT by saracatinib\/capivasertib co-delivery nanoparticles to improve the efficacy of anti-src therapy in head and neck squamous cell carcinoma","volume":"12","author":"Lang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.slasd.2026.100322_bib0018","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3390\/life12040580","article-title":"Galvanotactic migration of glioblastoma and brain metastases cells","volume":"12","author":"Lange","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.slasd.2026.100322_bib0019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"The emerging role of capivasertib in breast cancer","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.slasd.2026.100322_bib0020","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-21-1656","article-title":"Phase ib dose expansion and translational analyses of Olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer","volume":"27","author":"Westin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.slasd.2026.100322_bib0021","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall survival update for patients with metastatic castration-resistant prostate cancer treated with CAPIVASERTIB and Docetaxel in the phase 2 ProCAID clinical trial","volume":"82","author":"Crabb","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.slasd.2026.100322_bib0022","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1186\/s12885-025-14982-4","article-title":"A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.slasd.2026.100322_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.13042","article-title":"Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models","volume":"39","author":"Long","year":"2025","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.slasd.2026.100322_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33567","article-title":"Capivasertib reverses chemotherapy-induced esophageal cancer resistance via inhibiting Akt-associated Mcl-1 upregulation","volume":"10","author":"Kai","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.slasd.2026.100322_bib0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/cells9030533","article-title":"Circumventing AKT-associated radioresistance in oral cancer by novel nanoparticle-encapsulated Capivasertib","volume":"9","author":"Lang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.slasd.2026.100322_bib0026","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202502319RR","article-title":"EBV-LMP1 promotes the progression of nasopharyngeal carcinoma via TNC-mediated activation of PI3K\/Akt pathway","volume":"39","author":"Zhang","year":"2025","journal-title":"FASEB J"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555226000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:53:44Z","timestamp":1785912824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555226000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"alternative-id":["S2472555226000286"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100322","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-versus-nonmalignant quantitative drug sensitivity profiling identifies capivasertib as a selective therapeutic candidate for nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2026.100322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100322"}}